Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Cash (2017 - 2025)

Historic Change in Cash for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$54.8 million.

  • Protagonist Therapeutics' Change in Cash rose 7557.79% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 8255.03%. This contributed to the annual value of -$89.5 million for FY2024, which is 24672.61% down from last year.
  • Latest data reveals that Protagonist Therapeutics reported Change in Cash of -$54.8 million as of Q3 2025, which was up 7557.79% from $29.0 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Change in Cash high stood at $183.1 million for Q2 2024, and its period low was -$224.5 million during Q3 2024.
  • Moreover, its 5-year median value for Change in Cash was -$4.9 million (2023), whereas its average is -$200947.4.
  • Per our database at Business Quant, Protagonist Therapeutics' Change in Cash plummeted by 452455.2% in 2024 and then surged by 39948.44% in 2025.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Change in Cash stood at $3.1 million in 2021, then tumbled by 966.86% to -$27.1 million in 2022, then plummeted by 61.79% to -$43.8 million in 2023, then increased by 22.67% to -$33.9 million in 2024, then tumbled by 61.88% to -$54.8 million in 2025.
  • Its Change in Cash was -$54.8 million in Q3 2025, compared to $29.0 million in Q2 2025 and $42.4 million in Q1 2025.